Condition
Acute Interstitial Nephritis
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Not Yet Recruiting1
Withdrawn1
Unknown1
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07683975Phase 4Not Yet Recruiting
Infliximab for Immune Checkpoint Inhibitor Associated AKI
NCT04343417Enrolling By Invitation
Biorepository to Support Research in Kidney Diseases
NCT05233241Not ApplicableUnknownPrimary
Identification of the Causative Drug in Drug-induced Acute Interstitial Nephritis
NCT01893658Phase 2WithdrawnPrimary
Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)
Showing all 4 trials